Axsome Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Axsome Therapeutics
AXSM Stock  USD 124.76  0.92  0.73%   
Axsome Therapeutics financial statements provide useful quarterly and yearly information to potential Axsome Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Axsome Therapeutics financial statements helps investors assess Axsome Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Axsome Therapeutics' valuation are summarized below:
Gross Profit
352.4 M
Profit Margin
(0.74)
Market Capitalization
6.1 B
Enterprise Value Revenue
15.5731
Revenue
385.7 M
There are over one hundred nineteen available fundamental signals for Axsome Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Axsome Therapeutics' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 4.3 B. Also, Enterprise Value is likely to grow to about 4.1 B

Axsome Therapeutics Total Revenue

404.98 Million

Check Axsome Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axsome Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 M, Interest Expense of 3.3 M or Selling General Administrative of 431.9 M, as well as many indicators such as Price To Sales Ratio of 9.99, Dividend Yield of 0.0 or PTB Ratio of 74.66. Axsome financial statements analysis is a perfect complement when working with Axsome Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Axsome Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Short and Long Term Debt Total201.1 M191.5 M53.1 M
Slightly volatile
Other Current Liabilities163.1 M155.3 M31.1 M
Slightly volatile
Total Current Liabilities241.6 M230.1 M51.8 M
Slightly volatile
Accounts Payable75.6 M72 M17.4 M
Slightly volatile
Cash331.1 M315.4 M116.7 M
Slightly volatile
Cash And Short Term Investments331.1 M315.4 M116.7 M
Slightly volatile
Common Stock Total Equity2.7 K4.3 K2.5 K
Slightly volatile
Common Stock Shares Outstanding32 M47.9 M26.2 M
Slightly volatile
Other Current Assets12.6 M12 M2.7 M
Slightly volatile
Total Liabilities537.1 M511.5 M120.5 M
Slightly volatile
Total Current Assets509.3 M485.1 M149 M
Slightly volatile
Short Term Debt1.4 M1.8 M2 M
Slightly volatile
Common Stock3.4 K5.8 K2.7 K
Slightly volatile
Other Liabilities37.6 M35.8 M22.3 M
Slightly volatile
Current Deferred Revenue12.4 M11.8 M5.4 M
Slightly volatile
Non Current Assets Total87.6 M83.4 M21.6 M
Slightly volatile
Non Currrent Assets Other20.1 M19.1 M4.1 M
Slightly volatile
Long Term Debt189.7 M180.7 M50.6 M
Slightly volatile
Non Current Liabilities Total295.4 M281.4 M70.6 M
Slightly volatile
Short and Long Term Debt2.2 M2.3 M2.9 M
Slightly volatile
Property Plant And Equipment Net5.7 M5.4 M1.4 M
Slightly volatile
Property Plant And Equipment Gross6.3 M6 M1.5 M
Slightly volatile
Property Plant Equipment1.4 M1.3 M354.2 K
Slightly volatile
Long Term Debt Total59.3 M56.5 M25.3 M
Slightly volatile
Capital Surpluse264.6 M488.5 M216.3 M
Slightly volatile
Net Invested Capital174.7 M237.7 M102 M
Slightly volatile
Net Working Capital167.3 M255 M96.6 M
Slightly volatile
Capital Stock4.5 K5.8 K3.6 K
Slightly volatile
Capital Lease Obligations12.9 M12.2 M3.4 M
Slightly volatile
Non Current Liabilities Other54.1 M91.7 M18 M
Slightly volatile

Axsome Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization8.3 M7.9 M2.5 M
Slightly volatile
Interest Expense3.3 M6.6 M2.5 M
Slightly volatile
Selling General Administrative431.9 M411.4 M82.9 M
Slightly volatile
Other Operating Expenses699.6 M666.3 M155.9 M
Slightly volatile
Research Development196.4 M187.1 M50.2 M
Slightly volatile
Total Operating Expenses664.6 M633 M149.7 M
Slightly volatile
Interest Income1.2 M1.4 M1 M
Slightly volatile
Reconciled Depreciation8.4 M8 M1.8 M
Slightly volatile
Selling And Marketing Expenses74.6 M115.3 M46.8 M
Slightly volatile

Axsome Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation89.5 M85.2 M20.2 M
Slightly volatile
Begin Period Cash Flow405.5 M386.2 M101.3 M
Slightly volatile
Total Cash From Financing Activities99.5 M57.8 M74.7 M
Slightly volatile
End Period Cash Flow331.1 M315.4 M116.7 M
Slightly volatile
Depreciation8.4 M8 M1.9 M
Slightly volatile
Issuance Of Capital Stock38.7 M40.8 M59.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.9910.51153.0352
Slightly volatile
Days Sales Outstanding197134252
Slightly volatile
Average Payables24.5 M23.3 M10.3 M
Slightly volatile
Stock Based Compensation To Revenue0.440.22090.6684
Slightly volatile
Capex To Depreciation0.0930.09792.6191
Slightly volatile
EV To Sales9.6810.1951.2258
Slightly volatile
Inventory Turnover1.342.11691.3013
Slightly volatile
Days Of Inventory On Hand252172286
Slightly volatile
Payables Turnover0.490.46260.1167
Slightly volatile
Sales General And Administrative To Revenue1.820.952.2373
Slightly volatile
Average Inventory4.8 M8.8 M3.2 M
Slightly volatile
Research And Ddevelopement To Revenue0.740.4851.0401
Slightly volatile
Capex To Revenue7.0E-47.0E-40.0116
Slightly volatile
Cash Per Share6.916.58163.0906
Slightly volatile
Days Payables Outstanding75078992.4 K
Slightly volatile
Income Quality0.810.44710.7441
Slightly volatile
Intangibles To Total Assets0.150.10370.1943
Slightly volatile
Current Ratio2.02.1083.9983
Very volatile
Receivables Turnover1.842.71611.5415
Slightly volatile
Capex Per Share0.00440.00560.0042
Slightly volatile
Revenue Per Share4.068.04972.1291
Slightly volatile
Interest Debt Per Share4.344.13451.3725
Slightly volatile
Operating Cycle449307538
Slightly volatile
Days Of Payables Outstanding75078992.4 K
Slightly volatile
Ebt Per Ebit1.161.02341.0803
Slightly volatile
Quick Ratio1.942.03973.9807
Very volatile
Net Income Per E B T1.121.00031.0273
Slightly volatile
Cash Ratio1.31.37053.7666
Very volatile
Days Of Inventory Outstanding252172286
Slightly volatile
Days Of Sales Outstanding197134252
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00210.9899
Slightly volatile
Fixed Asset Turnover40.2671.650244.7891
Pretty Stable
Price Sales Ratio9.9910.51153.0352
Slightly volatile
Asset Turnover0.340.67840.2151
Slightly volatile
Gross Profit Margin0.720.91370.8867
Slightly volatile

Axsome Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.3 B4.1 B1.5 B
Slightly volatile
Enterprise Value4.1 B3.9 B1.4 B
Slightly volatile

Axsome Fundamental Market Drivers

Cash And Short Term Investments315.4 M

Axsome Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Axsome Therapeutics Financial Statements

Axsome Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Axsome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11.8 M12.4 M
Total Revenue385.7 M405 M
Cost Of Revenue33.3 M35 M
Stock Based Compensation To Revenue 0.22  0.44 
Sales General And Administrative To Revenue 0.95  1.82 
Research And Ddevelopement To Revenue 0.49  0.74 
Revenue Per Share 8.05  4.06 
Ebit Per Revenue(0.73)(0.76)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
How To Invest In Axsome
Details
Is Axsome Stock a good investment?
Details
What is Axsome Therapeutics' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.99)
Revenue Per Share
8.05
Quarterly Revenue Growth
0.66
Return On Assets
(0.27)
Return On Equity
(2.32)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY